Back to News
Market Impact: 0.25
Biotech Gainers: SMMT, CELU, BDSX, CRDL And EDSA Advance On Company-Specific Catalysts
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsAnalyst InsightsCorporate EarningsRegulation & Legislation
Biotech/healthcare stocks were among today’s top gainers as Summit Therapeutics rallied on positive Phase III HARMONi trial data. Celularity moved despite a Nasdaq compliance notice, while Biodesix gained support from strong quarterly growth. Overall tone is modestly positive, though the article provides limited details on the magnitude of results beyond the trial “positive” readout.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BDSX0.15
CELU-0.20
CRDL0.45
SMMT0.35
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- AI's Supercharging a Scam Economy Bigger Than the Cocaine Trade
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- European bank stocks slide 8% as bond yields spark investor caution